The information may be unavailable due to the results not being approved or confirmed. In particular, when a call includes regions where projects are cofunded by EC funds and others where that is not the case, confirmation or approval may be not simultaneous.
Telomeric R-loop-mediated recombination in the alternative lengthening of telomeres pathway: towards designing novel therapeutic avenues for cancer therapy. Bruno Adriano Sousa Silva, Instituto de Medicina Molecular João lobo Antunes (IMM/FM/ULisboa). €239,854.
Physiopathology and clinical implications of the RANK c.1386C>T (R450W) mutation in breast cancer patients. Sandra Cristina Cara de Anjo Casimiro, Instituto de Medicina Molecular João lobo Antunes (IMM/FM/ULisboa). €239,615.
Targeting Intra-Tumor Heterogeneity as a promising therapeutic strategy for cancer. Ana Rita Grosso, NOVA.ID.FCT - Associação para a Inovação e Desenvolvimento da FCT (NOVA.ID.FCT). €239,479.
Detect, prevent, eradicate: a multi-step strategy to abrogate brain metastasization of breast cancer. Maria Alexandra de Oliveira Silva Braga Pedreira de Brito, FARM-ID, Associação da Faculdade de Farmácia para a Investigação e Desenvolvimento (FARM-ID). €239,860.
How cholesterol favors breast cancer intravasation and metastization. Sérgio Dias, Instituto de Medicina Molecular João lobo Antunes (IMM/FM/ULisboa). €190,615.
Origin and consequences of centrosome abnormalities in early human tumorigenesis. Carla Alexandra Mendes Lopes, Fundação Calouste Gulbenkian (FCG). €219,671.
Studying and targeting the non-coding functions of p53 mRNA in carcinogenesis. Marco Candeias, FCiências.ID - Associação para a Investigação e Desenvolvimento de Ciências (Fciências.ID). €232,199.
Using genomics to identify novel targeted therapies in brain metastases. Cláudia Maria Coelho de Faria, Instituto de Medicina Molecular João lobo Antunes (IMM/FM/ULisboa). €238,740.